JP2019535826A - 心血管疾患及び肺疾患を治療するためのグルコース−６−リン酸デヒドロゲナーゼの阻害剤 - Google Patents

心血管疾患及び肺疾患を治療するためのグルコース−６−リン酸デヒドロゲナーゼの阻害剤 Download PDF

Info

Publication number
JP2019535826A
JP2019535826A JP2019547229A JP2019547229A JP2019535826A JP 2019535826 A JP2019535826 A JP 2019535826A JP 2019547229 A JP2019547229 A JP 2019547229A JP 2019547229 A JP2019547229 A JP 2019547229A JP 2019535826 A JP2019535826 A JP 2019535826A
Authority
JP
Japan
Prior art keywords
formula
g6pd
pulmonary
compound
cardiovascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019547229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535826A5 (https=
Inventor
グプテ，サチン，エー．
Original Assignee
アイコア，エルエルシー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイコア，エルエルシー． filed Critical アイコア，エルエルシー．
Publication of JP2019535826A publication Critical patent/JP2019535826A/ja
Publication of JP2019535826A5 publication Critical patent/JP2019535826A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2019547229A 2016-11-16 2017-11-15 心血管疾患及び肺疾患を治療するためのグルコース−６−リン酸デヒドロゲナーゼの阻害剤 Pending JP2019535826A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662422929P 2016-11-16 2016-11-16
US62/422,929 2016-11-16
PCT/US2017/061741 WO2018093856A1 (en) 2016-11-16 2017-11-15 Inhibitors of glucose-6-phosphate dehydrogenase for treating cardiovascular and pulmonary conditions

Publications (2)

Publication Number Publication Date
JP2019535826A true JP2019535826A (ja) 2019-12-12
JP2019535826A5 JP2019535826A5 (https=) 2020-12-24

Family

ID=62145797

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019547229A Pending JP2019535826A (ja) 2016-11-16 2017-11-15 心血管疾患及び肺疾患を治療するためのグルコース−６−リン酸デヒドロゲナーゼの阻害剤

Country Status (4)

Country Link
US (2) US11185552B2 (https=)
EP (1) EP3542160B1 (https=)
JP (1) JP2019535826A (https=)
WO (1) WO2018093856A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10246711B2 (en) 2016-11-16 2019-04-02 Rakhee Gupte RNAi inhibitors of glucose-6-phosphate dehydrogenase for treating cardiovascular and pulmonary conditions
US12014835B2 (en) 2020-02-19 2024-06-18 Vanderbilt University Methods for evaluating therapeutic benefit of combination therapies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60025526T2 (de) 1999-11-16 2006-08-24 Genentech, Inc., South San Francisco Elisa für vegf
WO2002085297A2 (en) * 2001-04-24 2002-10-31 East Carolina University Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
KR20060054233A (ko) 2006-04-07 2006-05-22 박상봉 액정디스플레이용 보강패널 및 그 제조방법
WO2007117048A1 (en) * 2006-04-10 2007-10-18 Seoul National University Industry Foundation Inhibitors against g6pd enzyme for treating and preventing oxidative stress and/or inflammatory related diseases and method for screening the same
EP2101567A4 (en) * 2007-01-18 2010-04-21 Univ Utah Res Found COMPOSITIONS AND METHODS FOR DETECTING, TREATING OR PREVENTING REDUCED STRESS
WO2011127465A2 (en) * 2010-04-09 2011-10-13 The Research Foundation Of The State University Of New York Ship inhibitors and uses thereof
PL2709631T3 (pl) 2011-05-20 2017-07-31 Inserm - Institut National De La Santé Et De La Recherche Médicale Antagoniści receptora cb1

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AM J PHYSIOL LUNG CELL MOL PHYSIOL, vol. 308, JPN6021033434, 2015, pages 287 - 300, ISSN: 0004821988 *
CURRENT OPINION IN INVESTIGATIONAL DRUGS, vol. 9, no. 9, JPN6021033435, 2008, pages 993 - 1000, ISSN: 0004821989 *
NIALL M. HAMILTON: "NOVEL STEROID INHIBITORS OF GLUCOSE 6-PHOSPHATE DEHYDROGENASE", JOURNAL OF MEDICINAL CHEMISTRY, vol. 55, JPN5020001223, 2012, pages 4431 - 4445, XP055486643, ISSN: 0004821987, DOI: 10.1021/jm300317k *

Also Published As

Publication number Publication date
US20190290659A1 (en) 2019-09-26
EP3542160A4 (en) 2020-06-24
WO2018093856A1 (en) 2018-05-24
US20220040202A1 (en) 2022-02-10
EP3542160B1 (en) 2025-01-01
EP3542160A1 (en) 2019-09-25
US11185552B2 (en) 2021-11-30

Similar Documents

Publication Publication Date Title
JP7708772B2 (ja) エストロゲン受容体関連疾患の治療方法
Sun et al. LncRNA PCFL promotes cardiac fibrosis via miR-378/GRB2 pathway following myocardial infarction
BR112014018355B1 (pt) Composto inibidor de quinase reguladora de sinal de apoptose, composição farmacêutica compreendendo o referido composto, uso e compostos intermediários do mesmo
KR20100099158A (ko) 심근세포 생존과 심장 회복을 제어하는 ＭＩＲ-15 집단의 마이크로ＲＮＡｓ
WO2014117697A1 (zh) 微小rna或其抑制剂在脂代谢调控中的应用
US9763916B2 (en) Methods and compositions involving (S)-bucindolol
US10772974B2 (en) Compositions and methods for cardiac regeneration
Feng et al. A novel decalin-based bicyclic scaffold for FKBP51-selective ligands
US20220040202A1 (en) Inhibitors of glucose-6-phosphate dehydrogenase for treating cardiovascular and pulmonary conditions
KR101501576B1 (ko) Ｈｉｆ-1 활성을 저해하는 아릴옥시페녹시아세틸계 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
US20240307347A1 (en) Antitumor tet2 modulating compounds
EP3059231B1 (en) Chromene derivatives as inhibitors of tcr-nck interaction
KR20150079616A (ko) 암 치료를 위한 베타-하이드록실라제의 억제제
CN107531598B (zh) 用于治疗纤维化和纤维化相关病症的组合物
KR20220047807A (ko) 근육 소모 및 다른 상태의 치료 및 예방에 적합한 화합물
JP5694959B2 (ja) 三位で置換された３−ベンゾフラニル−インドール−２−オン誘導体、この調製およびこの治療的使用
US10246711B2 (en) RNAi inhibitors of glucose-6-phosphate dehydrogenase for treating cardiovascular and pulmonary conditions
EA022158B1 (ru) Модуляторы активности гидролазы амидов жирных кислот
ES2809487T3 (es) 1,4-di-(4-metiltiofenil)-3-ftaloilazetidin-2-ona y sus derivados
HK40081119B (en) Compositions for use in a method of treating an estrogen receptor associated cancer
HK40081119A (en) Compositions for use in a method of treating an estrogen receptor associated cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210827

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220711